Peptide Initiative

Peptide history · 1992

Exenatide (Byetta / Bydureon)

The Lizard Venom That Launched a Diabetes Revolution

FDA Approved1952 – 2014

A poisonous desert lizard, a stubborn scientist in a Bronx VA hospital, and a government that refused to patent the discovery — this is the unlikely story of how Gila monster spit became one of the most important diabetes drugs ever made.

1992Discovery

Found in Gila monster venom by Dr. John Eng

2005FDA Approval

First GLP-1 drug ever approved (Byetta)

39Amino Acids

53% identical to human GLP-1

4,187 DaMolecular Weight

Daltons

Gila MonsterOrigin

Heloderma suspectum venom

$678MPeak Sales

US peak in 2008

  • Dr. John Eng

    The Lizard Venom Detective · Bronx VA Medical Center

    Working alone in a modest VA hospital lab in the Bronx, Eng ordered dried Gila monster venom from a Utah serpentarium through a catalog. In 1992, he discovered exendin-4 — a hormone in the venom that controlled blood sugar. When the VA refused to patent it, Eng paid for the patent himself and spent years finding someone willing to develop it into a drug.

    I thought the VA would be excited. Instead, they showed no interest in patenting it. So I did it myself. I believed in this molecule.
  • Dr. Jean-Pierre Raufman

    The First Clue · National Institutes of Health

    In the 1980s, Raufman at the NIH discovered that Gila monster venom could make the pancreas grow larger. This early finding caught John Eng's attention and set him on the path to studying what was hiding in the lizard's spit.

    We noticed something strange about Gila monster venom — it was making pancreatic cells grow and multiply. Something in that venom was sending powerful signals.
  • Amylin Pharmaceuticals Team

    The Believers · San Diego, California

    After every major drug company turned Eng down, the small biotech startup Amylin Pharmaceuticals took a chance on exendin-4. Their team turned the lizard hormone into a synthetic drug called exenatide, ran the clinical trials, and brought Byetta to market in 2005 — creating an entirely new class of diabetes medicines.

    Everyone told us a diabetes drug from lizard venom was crazy. We thought it was brilliant.

  1. The Discovery

    Diabetes Without Answers

    A Growing Crisis With Shrinking Options

    Key moment

    10+ million Americans with type 2 diabetes by 1990

    By the early 1990s, type 2 diabetes was spreading across America like wildfire. More than 10 million people had it, and the number was climbing every year. The treatments available were frustrating at best and dangerous at worst.

    Insulin injections were the gold standard, but they caused weight gain and could make blood sugar crash to dangerously low levels. Pills like sulfonylureas pushed the pancreas harder and harder to make insulin, eventually wearing it out. Metformin helped, but many patients needed more.

    Doctors were stuck. They needed a drug that could lower blood sugar without the constant risk of crashes, without causing weight gain, and ideally one that could help the exhausted pancreas recover. That drug existed — but it was hiding in the mouth of a poisonous lizard in the Arizona desert.

  2. The Breakthrough

    The Bronx Lab

    A Scientist, A Catalog, and A Lizard

    Key moment

    Venom ordered by mail from a Utah serpentarium

    Dr. John Eng was an endocrinologist at the Veterans Affairs Medical Center in the Bronx, New York. He had developed a technique to screen animal venoms for new hormones — and he was looking for something no one else thought to search for.

    Earlier NIH research had shown that Gila monster venom could make the pancreas enlarge. Eng was fascinated. The Gila monster is one of only two venomous lizards on Earth. It eats just three or four times a year, yet somehow keeps its blood sugar perfectly controlled between meals. Eng suspected the answer was in its venom.

    He ordered dried venom samples from a serpentarium in Utah — through a mail-order catalog, of all things. Working in his modest Bronx lab, he ran his chemical screening tests. In 1992, the results came back: the venom contained a brand-new hormone he named exendin-4. It looked remarkably similar to human GLP-1 — but with one critical difference. While natural GLP-1 fell apart in the bloodstream in two minutes, exendin-4 lasted for hours. The lizard had already solved the problem that was stumping every scientist in the field.

  3. The Trials

    Nobody Wanted It

    A Discovery Abandoned By Its Own Government

    Key moment

    VA refused to patent — Eng paid for it himself

    What happened next would frustrate Eng for years. He brought his discovery to the VA, expecting excitement. Instead, they showed no interest in patenting exendin-4. The government agency that funded his lab saw no commercial potential in a hormone from lizard spit.

    So Eng took an extraordinary step: he paid for the patent himself, using his own money. Then he began knocking on doors at pharmaceutical companies. One after another, they turned him down. A diabetes drug from lizard venom? It sounded too strange, too risky.

    For nearly three years, Eng struggled. Then, in 1996, at a scientific meeting in San Francisco, he pinned up a poster showing how exendin-4 lowered blood sugar in diabetic mice. A small biotech company called Amylin Pharmaceuticals — based in San Diego and already working on a similar gut hormone called amylin — saw the poster and made a deal. They would turn Eng's lizard hormone into a real drug.

    Amylin created a synthetic version called exenatide, identical to the natural Gila monster peptide, and began the long, expensive process of clinical trials.

  4. The Crisis

    The Pancreatitis Shadow

    Success Meets Suspicion

    Key moment

    First-ever GLP-1 drug approved — then pancreatitis fears hit

    On April 28, 2005, the FDA approved Byetta — making exenatide the first GLP-1 drug in history. Patients injected it twice daily before meals, and the results were impressive: lower blood sugar, weight loss instead of weight gain, and far fewer dangerous blood sugar crashes than insulin.

    But success brought scrutiny. In 2007, reports of acute pancreatitis — painful, sometimes deadly inflammation of the pancreas — began appearing in Byetta users. The FDA added warnings to the label. Headlines questioned whether the drug was safe. Some researchers pointed to a possible link between GLP-1 drugs and pancreatic cancer, though the evidence was thin.

    Amylin Pharmaceuticals fought back with data showing the pancreatitis rate was no higher than in diabetic patients not taking the drug. But the damage to public confidence was real. The company's stock dropped. Doctors hesitated to prescribe it. The first GLP-1 drug ever approved was fighting for its reputation.

  5. The Legacy

    The Door It Opened

    From Twice Daily to Once Weekly — and Beyond

    Key moment

    Golden Goose Award for curiosity-driven research that changed medicine

    Amylin didn't give up. They developed Bydureon — an extended-release version of exenatide that patients needed only once per week instead of twice daily. The FDA approved it in 2012. The convenience was a game-changer, and it proved that GLP-1 drugs could be redesigned for easier use.

    But exenatide's greatest legacy isn't the drug itself — it's what it proved was possible. By showing that a GLP-1 drug could safely lower blood sugar, cause weight loss, and avoid dangerous crashes, Byetta opened the floodgates. Liraglutide (Victoza) followed. Then semaglutide (Ozempic, Wegovy). Then tirzepatide (Mounjaro). Each one built on the foundation that a stubborn scientist in a Bronx VA hospital had laid.

    In 2013, Eng received the Golden Goose Award — given to scientists whose quirky, curiosity-driven research led to major breakthroughs. The committee's message was clear: sometimes the most important discoveries come from the most unexpected places. Like the mouth of a poisonous desert lizard.

    Today, GLP-1 drugs are the fastest-growing class of medicines in the world. It all started with a mail-order venom sample and a scientist who wouldn't take no for an answer.

14 milestones, 1952 – 2014.

  1. 1952Scientists first study Gila monster venom and notice it affects the digestive system
  2. 1983GLP-1 is discovered hiding in the glucagon gene by Joel Habener's team
  3. 1986NIH researcher Raufman shows Gila monster venom can make the pancreas grow
  4. 1990John Eng begins screening Gila monster venom for hormones at the Bronx VA
  5. 1992Eng discovers exendin-4 in Gila monster venom — 53% identical to human GLP-1
  6. 1993VA refuses to patent the discovery; Eng files and pays for the patent himself
  7. 1996Amylin Pharmaceuticals licenses exendin-4 after seeing Eng's poster at a conference
  8. 2000Clinical trials of synthetic exenatide (Byetta) begin in humans
  9. 2005FDA approves Byetta — the first GLP-1 receptor agonist drug in history
  10. 2007FDA adds pancreatitis warning to Byetta's label after post-market reports
  11. 2008Byetta US sales peak at $678 million
  12. 2012FDA approves Bydureon — the first once-weekly GLP-1 drug
  13. 2013John Eng receives the Golden Goose Award for his lizard venom discovery
  14. 2014AstraZeneca acquires rights; Bydureon BCise auto-injector launched

Imagine a lizard that eats only three or four times a year. To survive long stretches without food, the Gila monster makes a special substance in its spit that controls blood sugar with incredible precision. Exenatide is a lab-made copy of that lizard hormone — and it works in humans too.

Molecular structure

Amino Acids
39
Molecular Weight
4,187 Da
Similarity to GLP-1
53%
Half-life (Byetta)
~2.4 hours
Formula
C₁₈₄H₂₈₂N₅₀O₆₀S
DPP-4 Resistant
Yes

$678MPeak US Sales

2008 — Byetta alone

1stFirst GLP-1 Drug Approved

April 28, 2005

2M+Patients Treated

Within first 5 years of approval

80+Countries with Access

Byetta and Bydureon

Real stories, real lives

  • Robert Chen

    I'd been on three different diabetes pills and my numbers were still terrible. My doctor suggested Byetta, and I remember thinking — a drug from lizard venom? Really? But within two months my blood sugar was under control for the first time in years. I lost 12 pounds too. That lizard saved my life.
  • Linda Holloway

    The twice-daily Byetta injections were hard to keep up with. When Bydureon came out — one shot per week — it changed everything. I set a reminder every Sunday morning, take my shot, and don't think about it until the next week. My last three checkups have been the best numbers I've had in a decade.

The future of Exenatide

  • Alzheimer's Disease TrialsPhase 3

    Exenatide is being tested as a treatment for Alzheimer's and Parkinson's disease — researchers believe it may protect brain cells

  • Next-Generation Lizard PeptidesResearch

    Scientists are studying other Gila monster venom components for potential new drugs

  • Improved Delivery SystemsDevelopment

    Implantable pumps and longer-acting formulations to reduce injection frequency even further

  • Combination TherapiesClinical Trials

    Exenatide combined with other hormones for even better blood sugar and weight control

Be inspired

The story of Exenatide is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Exenatide Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.